179 related articles for article (PubMed ID: 16635263)
1. Novel multi-component nanopharmaceuticals derived from poly(ethylene) glycol, retro-inverso-Tat nonapeptide and saquinavir demonstrate combined anti-HIV effects.
Wan L; Zhang X; Gunaseelan S; Pooyan S; Debrah O; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
AIDS Res Ther; 2006 Apr; 3():12. PubMed ID: 16635263
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of poly(ethylene glycol)-based saquinavir prodrug conjugates and assessment of release and anti-HIV-1 bioactivity using a novel protease inhibition assay.
Gunaseelan S; Debrah O; Wan L; Leibowitz MJ; Rabson AB; Stein S; Sinko PJ
Bioconjug Chem; 2004; 15(6):1322-33. PubMed ID: 15546199
[TBL] [Abstract][Full Text] [Related]
3. Targeting the sodium-dependent multivitamin transporter (SMVT) for improving the oral absorption properties of a retro-inverso Tat nonapeptide.
Ramanathan S; Pooyan S; Stein S; Prasad PD; Wang J; Leibowitz MJ; Ganapathy V; Sinko PJ
Pharm Res; 2001 Jul; 18(7):950-6. PubMed ID: 11496954
[TBL] [Abstract][Full Text] [Related]
4. Targeted PEG-based bioconjugates enhance the cellular uptake and transport of a HIV-1 TAT nonapeptide.
Ramanathan S; Qiu B; Pooyan S; Zhang G; Stein S; Leibowitz MJ; Sinko PJ
J Control Release; 2001 Dec; 77(3):199-212. PubMed ID: 11733088
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of chitosan nanoformulations as potent anti-HIV therapeutic systems.
Ramana LN; Sharma S; Sethuraman S; Ranga U; Krishnan UM
Biochim Biophys Acta; 2014 Jan; 1840(1):476-84. PubMed ID: 24121104
[TBL] [Abstract][Full Text] [Related]
7. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Schapiro JM; Winters MA; Lawrence J; Merigan TC
AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
[TBL] [Abstract][Full Text] [Related]
8. MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine.
Katlama C; Pellegrin JL; Lacoste D; Aquilina C; Raffi F; Pialoux G; Vittecoq D; Raguin G; Lantz O; Mouroux M; Calvez V; Trylesinski A; Montestruc F; Dohin E; Goehrs JM; Delfraissy JF
HIV Med; 2001 Jan; 2(1):20-6. PubMed ID: 11737372
[TBL] [Abstract][Full Text] [Related]
9. Single daily doses of saquinavir achieve HIV-inhibitory concentrations when combined with baby-dose ritonavir.
Kurowski M; Müller M; Donath F; Mrozikiewicz M; Möcklinghoff C
Eur J Med Res; 1999 Mar; 4(3):101-4. PubMed ID: 10085276
[TBL] [Abstract][Full Text] [Related]
10. Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS.
Shah LK; Amiji MM
Pharm Res; 2006 Nov; 23(11):2638-45. PubMed ID: 16969696
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein expression affects the intracellular concentration and antiviral activity of the protease inhibitor saquinavir in a T cell line.
Maffeo A; Bellomi F; Solimeo I; Bambacioni F; Scagnolari C; De Pisa F; Dupuis ML; Cianfriglia M; Antonelli G; Turriziani O
New Microbiol; 2004 Apr; 27(2 Suppl 1):119-26. PubMed ID: 15646074
[TBL] [Abstract][Full Text] [Related]
12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
13. Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type 1.
Falkensammer B; Fasser W; Scherer K; Zemann A; Parson W; Ulmer H; Dierich MP; Stoiber H
Int J Immunopathol Pharmacol; 2005; 18(1):145-54. PubMed ID: 15698519
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of folate anchored Saquinavir entrapped PLGA nanoparticles for anti-tumor activity.
Singh R; Kesharwani P; Mehra NK; Singh S; Banerjee S; Jain NK
Drug Dev Ind Pharm; 2015; 41(11):1888-901. PubMed ID: 25738812
[TBL] [Abstract][Full Text] [Related]
15. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
[TBL] [Abstract][Full Text] [Related]
16. Peptide-poly(L-lysine citramide) conjugates and their in vitro anti-HIV behavior.
Couffin-Hoarau AC; Aubertin AM; Boustta M; Schmidt S; Fehrentz JA; Martinez J; Vert M
Biomacromolecules; 2009 Apr; 10(4):865-76. PubMed ID: 19296658
[TBL] [Abstract][Full Text] [Related]
17. Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Cardiello PG; van Heeswijk RP; Hassink EA; Srasuebkul P; Mahanontharit A; Samor TM; Worarien W; Beijnen JH; Hoetelmans RM; Ruxrungtham K; Cooper DA; Lange JM; Phanuphak P
J Acquir Immune Defic Syndr; 2002 Apr; 29(5):464-70. PubMed ID: 11981362
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort.
Brunet C; Reliquet V; Jovelin T; Venisse N; Winer N; Bui E; Le Moal G; Perfezou P; De Saint Martin L; Raffi F
Med Mal Infect; 2012 Sep; 42(9):421-8. PubMed ID: 22938775
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
Cohen Stuart JW; Schuurman R; Burger DM; Koopmans PP; Sprenger HG; Juttmann JR; Richter C; Meenhorst PL; Hoetelmans RM; Kroon FP; Bravenboer B; Hamann D; Boucher CA; Borleffs JC
AIDS; 1999 May; 13(7):F53-8. PubMed ID: 10357371
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
